APAC Region Emerges as Global Clinical Trial Powerhouse with 50,000 Expected Studies
核心洞察
Clinical trial activity in the Asia-Pacific region is rising two to three times faster than in Europe, with 50,000 trials expected to be managed in the coming years requiring more than 20,000 individual registered product types.
Australia offers six-week trial approvals and generous R&D tax incentives making it a preferred site for Phase I activity, while South Korea received Won1tn ($680m) in multinational drugmaker investments in the last 12 months.
European manufacturers are struggling to meet surging APAC demand for commercial-grade pharmaceuticals and are now restricting product access to EU-only supply as global demand outpaces capacity.
The Asia-Pacific region is experiencing unprecedented growth in clinical trial activity, with studies rising two to three times faster than in Europe and positioning the region as a critical hub for global pharmaceutical development. According to George Vlachos, co-CEO and co-founder of clinical trial supply company Akesa (搜索), 50,000 trials are expected to be managed within the APAC region in the coming years, requiring more than 20,000 individual registered product types.
"The growth is undeniable, but the supply chains have not caught up," Vlachos warned at the 10th Annual Outsourcing in Clinical Trials and Clinical Trial Supply Korea meeting in Seoul.
Regional Investment and Infrastructure Drive Expansion
Several factors are fueling this dramatic expansion across APAC markets. Australia has emerged as a preferred destination for Phase I studies, offering six-week trial approvals and generous R&D tax incentives that create a rapid startup environment. Meanwhile, South Korea has attracted significant pharmaceutical investment, with Won1tn ($680m) deployed by multinational drugmakers in the last 12 months according to the Korea Research-Based Pharma Industry Association (搜索).
Japan's renewed biotech investment, supported by the country's Pharmaceuticals and Medical Devices Agency (PMDA), has also contributed to driving regional growth. China continues to surge as companies increasingly initiate early-phase studies in the region before expanding globally.
Vlachos noted that established hubs including Australia, Japan, South Korea and China will remain high-growth markets for the next 10-15 years, with India expected to follow closely. Emerging markets such as Indonesia, Vietnam, and the Philippines are positioning themselves to offer access to large treatment-naïve patient pools once infrastructure development is complete.
Supply Chain Vulnerabilities Emerge
The rapid expansion is exposing critical vulnerabilities in commercial supply chains that have not evolved to match the pace of growth. European manufacturers are struggling to meet the surging APAC demand for commercial-grade pharmaceuticals for trials, with some now restricting product access and approving supply only within the EU as they cannot meet rising global demand.
This supply constraint is compounded by increasing clinical activity in Latin America, further stretching European manufacturing capacity. Historically, sponsors relied on regional sourcing schemes, but the current model is proving inadequate for the scale of APAC expansion.
Radiopharmaceutical Sector Presents Additional Opportunities
The radiopharmaceutical market adds another dimension to APAC's clinical trial landscape, with the global market projected to exceed $10bn by 2030. Stacy Lee, senior global clinical project manager at Novotech (搜索), highlighted that the Asia-Pacific region follows closely behind the US as the fastest-growing region for radiopharmaceutical trials, particularly in China and Australia.
The past five years have seen a sharp rise in oncology trials researching radiopharmaceuticals, with 38% in Phase I and 49% in Phase II, indicating a rapidly evolving pipeline that creates both opportunity and pressure for multi-regional strategies.
Australia offers particular advantages for radiopharmaceutical trials through its streamlined Clinical Trial Notification (CTN) pathway, described as one of the fastest regulatory pathways globally. The country's Schedule 7 exemption enables working with smaller private radiopharmacies that follow GMP principles without needing full GMP licensing, offering quicker ethics reviews and faster startup times.
South Korea's advanced imaging capabilities and integrated radiopharmacy policies enable highly targeted feasibility studies and rapid site selection, with typical startup timelines of five to six months positioning the country as an effective bridge between fast-activating Australia and slower US sites.
Operational Challenges Require Strategic Adaptation
The surge in APAC trial activity brings significant operational pressures, including fragmented regulatory pathways with each country requiring distinct documentation, budgetary changes, and delays to start-up times and recruitment. Later-phase programs, especially in oncology, metabolic disease, and cardiovascular trials, are now routinely anchored in APAC due to faster enrollment and large treatment-naïve populations.
However, Phase III studies require significantly higher volumes of investigational medical product, comparators, and cold-chain infrastructure. "Unless supply chains evolve at the same pace, sponsors will face increasing delays, higher costs, and greater risk," Vlachos emphasized.
To address these challenges, experts recommend adopting regionalized sourcing strategies designed specifically for APAC's complexity, including multi-sourcing approaches that utilize both local and regional supply chain access points rather than over-stretched EU sources. Early engagement with APAC regulators for alignment on labeling, packaging, documentation, and acceptance pathways in each country is also critical.
Infrastructure Paradox in Specialized Therapies
For radiopharmaceutical trials specifically, Lee identified a "clinical infrastructure paradox" where highly time-sensitive radioisotopes are scarce and dependent on a small number of specialized facilities worldwide. Radioisotope shortages have forced enrollment pauses in Phase III studies, while short half-lives and limited product stability complicate logistics further.
Most radioligand therapies currently target prostate cancer, central nervous systems, lung and gastrointestinal cancers, and neuroendocrine tumors, but the field is seeing momentum toward new areas. The FDA's August release of draft guidance on oncology therapeutic radiopharmaceuticals signals regulatory efforts to align with clinical development advances.
The expansion of trials globally in countries with available infrastructure helps relieve pressure on overused sites and leverages various healthcare frameworks, including centralized networks and referral pathways for patient enrollment. Multi-region enrollment distributes operational burden compared to single-cluster sites in one region, while globally distributed site networks leverage regional strengths.